Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they plan to fully review the medicines supply market, particularly with regard to shortages of medicines and their costs.

There are no plans to fully review the medicines supply market. Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes, or distribution and regulatory issues. We have drawn on up-to-date intelligence and data on the root causes of medicine supply issues, with manufacturing problems being the most dominant root cause.

The resilience of UK supply chains is a key priority, and the Department and NHS England are committed to helping to build long term supply chain resilience for medicines. We are continually learning and seeking to improve the way we work, to both manage and help prevent supply issues and avoid shortages. The Department, working closely with NHS England, is taking forward a range of actions to improve our ability to mitigate and manage shortages and strengthen our resilience. As part of that work, we continue to engage with industry, the Medicines and Healthcare products Regulatory Agency, and other colleagues across the supply chain as we progress work to co-design and deliver solutions.